In 47 patients ECG tracings were recorded and cardiovascular values determined before therapy, during treatment with antidepressive agents after it had been in progress for at least 3 weeks, and 4 weeks after withdrawal of therapy. In a further 19 patients in whom antidepressive therapy could not be withdrawn, the same test battery was repeated after an average period of 13 months. No serious disturbances of cardiac rhythm were detected and certain changes in ECG criteria (prolongation of PR interval, widening of QRS complex, prolongation of QTc time and T-wave flattening) proved to be reversible. There was no difference between tricyclic and tetracyclic antidepressive agents. We are nevertheless of the opinion that ECG and cardiac function should be carefully monitored in elderly patients and in those on prolonged therapy with high doses of antidepressives. The results of this study are discussed and compared with previously published findings.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Few Patients Are Treated for Both Obesity and Depression.
South Med J
February 2025
From the Center for Value-Based Care Research, Cleveland Clinic.
Objectives: Understanding the epidemiology of treatment for patients with co-occurring depression and obesity can inform care quality. The objective of the study was to identify how patients with obesity and newly diagnosed depression are treated and whether treatment is associated with body mass index change.
Methods: This cohort study included adults with obesity and newly diagnosed depression who had ≥2 primary care visits between 2015 and 2020 at a large integrated health system.
Antidepressants versus placebo for generalised anxiety disorder (GAD).
Cochrane Database Syst Rev
January 2025
Department of Psychiatry and Department of Epidemiology and Biostatistics, Western University, St Thomas, Canada.
Background: Generalised anxiety disorder (GAD) is a mental health condition characterised by excessive anxiety and worry about everyday events. GAD is a common disorder and generally affects women twice as often as men. Treatments include various psychological and pharmacological therapies.
View Article and Find Full Text PDFArticle Synopsis
- Smoking is a significant public health issue in Tamil Nadu, causing preventable diseases and increasing healthcare costs, necessitating effective smoking cessation strategies in primary health care (PHC) settings.
- The study aims to evaluate the cost-effectiveness of three proposed smoking cessation strategies against the current standard strategy, focusing on various combinations of counseling, nicotine replacement therapy, and medications for smokers aged 15 and older.
- Results indicated that the current cessation strategy was more expensive than the proposed strategies, with two of them (PS1 and PS3) being more cost-effective, potentially leading to better resource allocation for smoking cessation efforts.
Optimal timing for lithium levels.
F1000Res
January 2025
Departments of Psychiatry, Neurology, Radiology, and Neuroscience, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.
Reddy and Reddy (2014) discuss the optimal timing for lithium levels in patients taking once-daily extended-release lithium formulations. They argue for blood sampling 24 h after the previous dose rather than the standard 12 h. I interpret the data quite differently.
View Article and Find Full Text PDFEsketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway.
Cell Biol Toxicol
January 2025
Laboratory of Neurobiology, Hebei Medical University, Shijiazhuang, 050017, China.
Esketamine, a newly developed antidepressant, is the subject of this research which seeks to explore its impact on depressive symptoms in neuropathic pain mice and the potential molecular mechanisms involved. Through transcriptome sequencing and bioinformatics analysis combined with in vivo studies, it was identified that esketamine markedly boosts the levels of the m6A methyltransferase METTL3 and the AMPA receptor GluA1 subunit. Esketamine activates METTL3, allowing it to bind with GluA1 mRNA, promoting m6A modification, thereby enhancing GluA1 expression at synapses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!